NVCR - NASDAQ
NovoCure Limited
$16.15
+2.1%NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
At a Glance
Live SnapshotNovoCure Limited Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
NovoCure Limited Cash Flow Statement
NVCR • NASDAQ
| NovoCure Limited Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-136.2M | -168.6M | -207M | -92.5M | -58.4M | 19.8M | -7.2M | -63.6M | -61.7M | -131.8M | -111.6M | -80.7M | -77.4M | |
14.7M | -14.4M | 11M | 10.6M | 10.3M | 9.2M | 8.5M | 9M | 7.7M | 5.7M | 3.2M | 2M | 1.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 3.9M | -270K | -519K | 407K | 241K | 5.7M | 46K | 23K | 19K | |
0.0 | 160M | 115.6M | 107M | 94.9M | 75.7M | 52.4M | 39.8M | 27.1M | 22.1M | 11.9M | 4.6M | 5.1M | |
87.7M | 932K | -22.4M | -6.1M | 3M | 3.3M | -2.2M | 1M | 252K | 155K | 1M | -19K | 11.5M | |
(0.0) | (23.5M) | (13.7M) | (5.5M) | (3.1M) | (0.0) | (11.2M) | (20.4M) | (10.3M) | (9.4M) | (1.5M) | (282K) | (689K) | |
-15.1M | -4.3M | 29.6M | 11.8M | 29.1M | -8.5M | -24.3M | 11.4M | -6.8M | -9.4M | -4.4M | -152K | 6.8M | |
-49M | -26.4M | -73.3M | 30.8M | 82.8M | 99.1M | 26.6M | -1.9M | -33.1M | -107.6M | -99.9M | -74.2M | -52.7M | |
INVESTING ACTIVITIES | |||||||||||||
-26.6M | -42.9M | -27.1M | -21.4M | -24.2M | -15M | -10.5M | -6.7M | -7.4M | -17.7M | -10.3M | -2.3M | -3.6M | |
(0.0) | (0.0) | (0.0) | (118.6M) | (120.7M) | (457.9M) | (41.2M) | (3.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-821.1M | -875.4M | -1B | -1.3B | -1.1B | -607.9M | -461.8M | -253.8M | -104M | -239.3M | -209M | -138M | (0.0) | |
1.3B | 778M | 1.2B | 1.2B | 958M | 150M | 420.7M | 255M | 120M | 270M | 104M | 93M | 15M | |
0.0 | 0.0 | 0.0 | -118.6M | -120.7M | -457.9M | -41.2M | -3.8M | -1.9M | -180K | -26K | 1.1M | -1M | |
(437.3M) | -140.2M | (184.1M) | -140M | -144.8M | -472.8M | -51.7M | -5.5M | (6.8M) | (12.8M) | -115.3M | -46.2M | (10.4M) | |
FINANCING ACTIVITIES | |||||||||||||
9.8M | 4.2M | 4.4M | 5.2M | 4.5M | 3.4M | 2.5M | 1.8M | 1.5M | 616K | 252.1M | 0.0 | 191.7M | |
-461M | 84M | -10K | -28K | -26K | 408.4M | -31K | 49.1M | -57K | 72.8M | 22.8M | -9K | -8.4M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -5K | (0.0) | (0.0) | |
-146K | 2.2M | 11.4M | 10.3M | 21.2M | 28.4M | 59.2M | 18.5M | 3.7M | 1.7M | 2M | 2.2M | 2K | |
-451.3M | 90.3M | 15.8M | 15.5M | 25.7M | 440.2M | 61.7M | 69.4M | 5.2M | 75.1M | 277M | 2.1M | 183.3M | |
CASH FLOW SUMMARY | |||||||||||||
394K | -174K | 131K | -97K | -188K | 247K | 26K | 27K | 8K | 10K | 0.0 | 0.0 | 0.0 | |
-62.7M | -76.5M | 126.7M | -93.8M | -36.6M | 66.8M | 36.7M | 62M | -21.2M | -19.6M | 61.8M | -118.3M | 141M | |
166.1M | 242.6M | 115.8M | 209.6M | 246.2M | 179.4M | 142.8M | 80.7M | 99.8M | 119.4M | 57.6M | 175.9M | 34.9M | |
103.4M | 166.1M | 242.6M | 115.8M | 209.6M | 246.2M | 179.4M | 142.8M | 78.6M | 99.8M | 119.4M | 57.6M | 175.9M | |
-75.7M | -69.2M | -100.4M | 9.4M | 58.6M | 84.2M | 16.1M | -8.6M | -40.5M | -125.3M | -110.2M | -76.6M | -56.3M |
SEC Filings
NVCR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | April 24, 2026 | November 24, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 |
Related Guides
Continue your NVCR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.